Oxford Endovascular, an Oxford, UK-based medtech startup, closed an GBP8m in Series A+ funding round.
The round was led by Parkwalk Advisors with participation from Norcliffe Capital, Oxford Science Enterprises (OSE), Vulpes and the University of Oxford.
The company intends to use the funds to take its medical device, OXIFLOW, a step closer to a First-In-Human clinical study, and furter scale up operations.
Led by Mike Karim, CEO, Oxford Endovascular is a spin-out from Oxford University, working to prevent brain haemorrhage by curing brain aneurysms, a condition that affects 1 in 50 persons. The company is advancing OxiFlow™️, a novel, next generation flow-diverter, that diverts blood flow away from intracranial aneurysms at risk of rupture. It places more accurately and safely than existing devices, reducing the risk of complications. It conforms better to blood vessels making more patients treatable
FinSMEs
20/05/2024